SMMT
USDSummit Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$17.780
Kõrge
$18.120
Madal
$17.370
Maht
2.88M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
13.0B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
4.10M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Summit Therapeutics to Present at Upcoming Investor Conferences
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
Guggenheim analyst Brad Canino reiterates Summit Therapeutics with a Buy and maintains $40 price target.
Summit Therapeutics Raises $500 Million in Private Placement
Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit,"
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
Barclays analyst Etzer Darout maintains Summit Therapeutics with a Underweight and raises the price target from $13 to $16.
HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics with a Buy and lowers the price target from $50 to $40.
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Conference Call to be Held at 8:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the
Seotud aktsiad
CNTX
Context Therapeutics Inc.
DTI
Drilling Tools International Corporation
SAVE
Spirit Airlines Inc.
BLDR
Builders FirstSource Inc.
HTD
John Hancock Tax Advantaged Dividend Income Fund Common Shares of Beneficial Interest
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.